395 related articles for article (PubMed ID: 33029633)
41. Polatuzumab vedotin pharmacokinetics in a hemodialysis patient with diffuse large B-cell lymphoma.
Yasuda H; Kaga N; Taka H; Ochiai T; Yamana T; Miura Y; Ishii M; Sasaki M; Ando J; Ando M
Cancer Chemother Pharmacol; 2024 Mar; 93(3):265-268. PubMed ID: 37750932
[TBL] [Abstract][Full Text] [Related]
42. Population pharmacokinetics and exposure-response analyses of polatuzumab vedotin in patients with previously untreated DLBCL from the POLARIX study.
Deng R; Gibiansky L; Lu T; Flowers CR; Sehn LH; Liu Q; Agarwal P; Liao MZ; Dere R; Lee C; Man G; Hirata J; Li C; Miles D
CPT Pharmacometrics Syst Pharmacol; 2024 Jun; 13(6):1055-1066. PubMed ID: 38622879
[TBL] [Abstract][Full Text] [Related]
43. Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experience.
Segman Y; Ribakovsky E; Avigdor A; Goldhecht Y; Vainstein V; Goldschmidt N; Harlev S; Horwitz N; Gutwein O; Gurion R; Itchaki G; Abadi U; Nemets A; Sofer O; Zektser M; Tadmor T; Dally N; Filanovsky K; Leiba M; Sarid N; Benyamini N; Herishanu Y; Ram R; Perry C; Avivi I
Leuk Lymphoma; 2021 Jan; 62(1):118-124. PubMed ID: 32981410
[TBL] [Abstract][Full Text] [Related]
44. Polatuzumab vedotin in relapsed / refractory aggressive B-cell lymphoma.
Varma G; Wang J; Diefenbach C
Expert Rev Anticancer Ther; 2022 Aug; 22(8):795-803. PubMed ID: 35726803
[TBL] [Abstract][Full Text] [Related]
45. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
Gravanis I; Tzogani K; van Hennik P; de Graeff P; Schmitt P; Mueller-Berghaus J; Salmonson T; Gisselbrecht C; Laane E; Bergmann L; Pignatti F
Oncologist; 2016 Jan; 21(1):102-9. PubMed ID: 26621039
[TBL] [Abstract][Full Text] [Related]
46. Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma in the real world.
Vodicka P; Benesova K; Janikova A; Prochazka V; Belada D; Mocikova H; Steinerova K; Duras J; Karban J; Hanackova V; Sykorova A; Obr A; Trneny M
Eur J Haematol; 2022 Aug; 109(2):162-165. PubMed ID: 35502609
[TBL] [Abstract][Full Text] [Related]
47. A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies.
Fanale MA; Forero-Torres A; Rosenblatt JD; Advani RH; Franklin AR; Kennedy DA; Han TH; Sievers EL; Bartlett NL
Clin Cancer Res; 2012 Jan; 18(1):248-55. PubMed ID: 22080439
[TBL] [Abstract][Full Text] [Related]
48. Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial.
de Bono JS; Concin N; Hong DS; Thistlethwaite FC; Machiels JP; Arkenau HT; Plummer R; Jones RH; Nielsen D; Windfeld K; Ghatta S; Slomovitz BM; Spicer JF; Yachnin J; Ang JE; Mau-Sørensen PM; Forster MD; Collins D; Dean E; Rangwala RA; Lassen U
Lancet Oncol; 2019 Mar; 20(3):383-393. PubMed ID: 30745090
[TBL] [Abstract][Full Text] [Related]
49. Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma.
Salles G; Gopal AK; Minnema MC; Wakamiya K; Feng H; Schecter JM; Wang M
Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):275-284. PubMed ID: 30795996
[TBL] [Abstract][Full Text] [Related]
50. US cost-effectiveness of polatuzumab vedotin, bendamustine and rituximab in diffuse large B-cell lymphoma.
Betts KA; Thuresson PO; Felizzi F; Du EX; Dieye I; Li J; Schulz M; Masaquel AS
J Comp Eff Res; 2020 Oct; 9(14):1003-1015. PubMed ID: 33028076
[No Abstract] [Full Text] [Related]
51. Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy.
Ogura M; Tobinai K; Hatake K; Uchida T; Kasai M; Oyama T; Suzuki T; Kobayashi Y; Watanabe T; Azuma T; Mori M; Terui Y; Yokoyama M; Mishima Y; Takahashi S; Ono C; Ohata J
Cancer Sci; 2010 Aug; 101(8):1840-5. PubMed ID: 20491780
[TBL] [Abstract][Full Text] [Related]
52. Cost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma.
Patel KK; Isufi I; Kothari S; Foss F; Huntington S
Leuk Lymphoma; 2020 Dec; 61(14):3387-3394. PubMed ID: 32835553
[TBL] [Abstract][Full Text] [Related]
53. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
[TBL] [Abstract][Full Text] [Related]
54. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.
Younes A; Bartlett NL; Leonard JP; Kennedy DA; Lynch CM; Sievers EL; Forero-Torres A
N Engl J Med; 2010 Nov; 363(19):1812-21. PubMed ID: 21047225
[TBL] [Abstract][Full Text] [Related]
55. First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors.
Strickler JH; Weekes CD; Nemunaitis J; Ramanathan RK; Heist RS; Morgensztern D; Angevin E; Bauer TM; Yue H; Motwani M; Parikh A; Reilly EB; Afar D; Naumovski L; Kelly K
J Clin Oncol; 2018 Nov; 36(33):3298-3306. PubMed ID: 30285518
[TBL] [Abstract][Full Text] [Related]
56. Antibody-drug conjugates for previously treated aggressive lymphomas: focus on polatuzumab vedotin.
Burke JM; Morschhauser F; Andorsky D; Lee C; Sharman JP
Expert Rev Clin Pharmacol; 2020 Oct; 13(10):1073-1083. PubMed ID: 32985934
[TBL] [Abstract][Full Text] [Related]
57. Polatuzumab vedotin-based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience.
Wang YW; Tsai XC; Hou HA; Tien FM; Liu JH; Chou WC; Ko BS; Chen YW; Lin CC; Cheng CL; Lo MY; Lin YC; Lu LC; Wu SJ; Kuo SH; Hong RL; Huang TC; Yao M
Ann Hematol; 2022 Feb; 101(2):349-358. PubMed ID: 34766217
[TBL] [Abstract][Full Text] [Related]
58. Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study.
Hamadani M; Collins GP; Caimi PF; Samaniego F; Spira A; Davies A; Radford J; Menne T; Karnad A; Zain JM; Fields P; Havenith K; Cruz HG; He S; Boni J; Feingold J; Wuerthner J; Horwitz S
Lancet Haematol; 2021 Jun; 8(6):e433-e445. PubMed ID: 34048682
[TBL] [Abstract][Full Text] [Related]
59. Brentuximab vedotin: a new age in the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma.
Minich SS
Ann Pharmacother; 2012 Mar; 46(3):377-83. PubMed ID: 22395252
[TBL] [Abstract][Full Text] [Related]
60. Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial.
Budde LE; Olszewski AJ; Assouline S; Lossos IS; Diefenbach C; Kamdar M; Ghosh N; Modi D; Sabry W; Naik S; Mehta A; Nakhoda SK; Smith SD; Dorritie K; Jia T; Pham S; Huw LY; Jing J; Wu H; Ead WS; To I; Batlevi CL; Wei MC; Chavez JC
Nat Med; 2024 Jan; 30(1):229-239. PubMed ID: 38072960
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]